

<u>GDSA-BE:</u> Modernizing Bioequivalence Assessment for Abbreviated New Drug Applications

Tao Bai Senior Advisor

Office of Bioequivalence (OB), Office of Generic Drugs (OGD) CDER | U.S. FDA SBIA Generic Drugs Forum – April 10-11, 2024

We Are OGD

Ask me why... "I make sure that the generic drug and the brand drug work the same." FDA

"The first time I was able to buy my son's inhaler as a generic and realized that my out of pocket dropped, I cried and was able to breathe a sigh of relief."

www.fda.gov

Need for Modernization - Technology Advancement

FDA

Outside World





GDSA-BE

(Generic Drug Structured Assessment – Bioequivalence)

Consistency | Standardization | Efficiency Knowledge Management



Regulatory Review







www.fda.gov

Need for Modernization- Challenges with Current Process



External

- Need for a more streamlined assessment process to better meet GDUFA* goals
- Increased expectations from Congress, generic applicants, and the public

Assessment

- A freestyle narrative-based bioequivalence (BE) assessment, which is in place for decades
- Labor intensive tasks to process data, conduct data analysis, and extract and supply standard information to the review templates
- Lack of a better practice for knowledge sharing and knowledge management



Needs for standardized and structured data submission in ANDA applications

* Generic Drug User Fee Act

OGD Strategic Priorities (2023 – 2028) Modernizing the Generic Drug Program

कें है

People

Foster an engaged organizational culture that attracts and retains a highly qualified, talented, and diverse workforce empowered to carry out the mission of OGD.

٢

V

Process

Modernize processes to enhance efficiency and consistency across the generic drug program.

Innovation

Promote innovation and excellence to enable the efficient development and approval of safe and effective generic drug products.

Champ

Lifecycle Engagement

Champion a shared vision and understanding of drug product lifecycle for optimal use of the 505(j) pathway.

from lilun Murphy's keynote at the AAM GRx + Biosims 2023 conference

GDSA-BE



Office of Generic Drugs 2023 Annual Report

Ensuring high-guality, safe, and effective generic drugs are available to the American Public



Modernizing the BE Assessment Process:

In 2023, OGD launched a new structured BE assessment tool – the Generic Drug Structured Assessment for Bioequivalence (GDSA-BE) - for two-way crossover in vivo pharmacokinetic (PK) BE studies for oral solid dosage form drug products. This tool officially signaled the change of bioequivalence assessment from narrative review to structured data with dynamic, interactive, and integrated collaboration capabilities. GDSA-BE is a BE assessment tool to enable a streamlined and efficient BE assessment and a powerful knowledge management tool, which aids consistent and well-informed regulatory decision making with direct access to multiple subject databases.

OGD Generic Drug Structured Assessment (GDSA)




-OGD Structured Review Templates in NEXUS (Appian) – Enterprise-level solution

Modernization of bioequivalence assessment from unstructured narrative *to* structured data with dynamic and interactive collaboration capabilities utilizing an integrated system.



enefits $\mathbf{\hat{\mathbf{m}}}$ **GDSA-**



Where is GDSA-BE Today



Releases

- V(1.0) Released on 12/12/2022
- V(1.1) Released on 9/18/2023
- V(1.2) Released on 3/25/2024

Assessments

 ~60 ANDA assessments completed in the system

Implementation

 Implemented fully in Office of Bioequivalence

Challenge Question



GDSA-BE (Generic Drug Structure Assessment – Bioequivalence) tool is (a):

- A. Generic Drug BE Review Tool
- B. BE Knowledge Management Tool
- C. Both

Summary



- Generic drug bioequivalence assessment is entering a *new era* GDSA-BE (Generic Drug Structured Assessment – Bioequivalence)
- GDSA-BE is both an intelligent review tool and a valuable knowledge management tool
- GDSA-BE enables an efficient and standardized BE assessment process and empowers an informed and consistent regulatory decision-making

